Adam Feuerstein

2 days ago | statnews.com | Adam Feuerstein |Elaine Chen |Allison DeAngelis

On this week’s episode of “The Readout LOUD”: The Food and Drug Administration’s AI adventure, a deep look inside Novo Nordisk’s obesity stumble, and finally, another big M&A deal in biotech. The FDA has rolled out an internal AI tool called Elsa that, unlike its namesake Disney character, can’t seem to let go of mistakes. Our colleague Brittany Trang joins to explain. And it’s always a fun podcast when we can discuss a biotech acquisition.

5 days ago | statnews.com | Adam Feuerstein |Matthew Herper |Angus Chen

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. ASCO ends tomorrow, but alas, dear readers, this newsletter’s run of show is over. At least until next year. Before you digest our parting words, a couple of housekeeping notes:

5 days ago | statnews.com | Adam Feuerstein

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but previously untreated breast cancer — study results reported Monday that the drug’s makers AstraZeneca and Daiichi Sankyo believe could change the way the disease is treated for the first time in a decade. Oncologists agree, and noted with astonishment that the efficacy of Enhertu and other drugs used to treat HER2-positive breast cancer can now be measured in years.

5 days ago | statnews.com | Adam Feuerstein

An experimental medicine from Vera Therapeutics significantly reduced levels of toxic protein in the urine of patients with an autoimmune kidney disease. The Phase 3 study results reported Monday met an intermittent treatment goal and laid down a marker ahead of a competing study readout later this week. The Vera drug called atacicept lowered proteinuria levels by 46% after nine months compared to 7% lowering in patients given a placebo.

6 days ago | statnews.com | Adam Feuerstein |Matthew Herper |Angus Chen

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. We’re going to get to today’s new data in a minute, but first let’s deal with a less serious matter: the marketing of pharmaceutical products via the food attendees need to consume at giant medical meetings. Genentech has been a longtime leader on this front.